CRS LNP-RNA Therapeutics Symposium 2022, April 6-7 Ossi Leppänen2022-04-06T16:42:59+02:00April 6th, 2022| Read More
DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product Ossi Leppänen2022-03-28T11:32:06+02:00March 28th, 2022| Read More
DelSiTech Ltd Announces Appointment of Mr. Kristian Rantala as Chief Financial Officer Ossi Leppänen2022-02-03T14:13:45+02:00February 3rd, 2022| Read More
BIO Europe Spring 2021, March 28-31 Ossi Leppänen2022-01-31T18:13:11+02:00January 31st, 2022| Read More
DelSiTech Ltd Announces the Appointment of Dr. Outi Heikkilä, as the New Director, Head of Manufacturing. Ossi Leppänen2022-01-28T12:13:31+02:00January 27th, 2022| Read More
Controlled & Modified Drug Release Summit 2022, March 1-2 Ossi Leppänen2022-04-06T18:40:49+02:00January 12th, 2022| Read More
Drug Delivery Company DelSiTech Ltd Announces Appointment of Mr. Martti Hedman to Its Board of Directors Ossi Leppänen2022-01-05T14:00:39+02:00January 5th, 2022| Read More
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare Ossi Leppänen2021-10-04T13:00:04+02:00October 4th, 2021| Read More
Partnering Opportunities in Drug Delivery 2021, October 28-29 Ossi Leppänen2021-10-01T17:04:01+02:00October 1st, 2021| Read More
